Cherry Thomas
Profile
Cherry T.
Thomas held several positions in clinical development at various biotech companies, including Executive Director at BeiGene Ltd., Vice President at Array BioPharma, Senior Vice President at Caribou Biosciences, and Vice President at Jounce Therapeutics.
Thomas received an undergraduate degree from the University of California, Los Angeles, and graduate degrees from The Johns Hopkins University and the University of California, Irvine.
Former positions of Cherry Thomas
| Companies | Position | End |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2022-02-28 |
| JOUNCE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
| BEIGENE, LTD. | Chief Tech/Sci/R&D Officer | - |
| ARRAY TECHNOLOGIES, INC. | Corporate Officer/Principal | - |
Training of Cherry Thomas
| University of California, Los Angeles | Undergraduate Degree |
| The Johns Hopkins University | Graduate Degree |
| University of California, Irvine | Graduate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 2 |
|---|---|
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| BEIGENE, LTD. | Health Technology |
| Private companies | 2 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Jounce Therapeutics, Inc.
 Jounce Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. | Commercial Services |
- Stock Market
- Insiders
- Cherry Thomas
